Inflammatory Myopathies with Anti-Ku Antibodies
Medicine 91:95-102, Rigolet,A.,et al, 2012
Cogan Syndrome An Analysis of Reported Neurological Manifestations
The Neurologist 18:55-63, Antonios,N. and Silliman,S., 2012
Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
NEJM 366:1000-1009, Comi,G.,et al, 2012
Cortical Pathology in Multiple Sclerosis Patients with Epilepsy: A 3 Year Longitudinal Study
JNNP 83:49-54, Calabrese, M.,et al, 2012
Cerebral Amyloid Angiopathy
eMedicine, Jan, Menon, R.S., 2012
Brain Abnormalities in Neuromyelitis Optica Spectrum Disorder
Multiple Sclerosis International ID 735486, Kim, W.,et al, 2012
Current Concept of Neuromyelitis Optica (NMO) and NMO Spectrum Disorders
JNNP doi:10.1136/JNNP-2012-302310, Jacob, A.,et al, 2012
The Differential Diagnosis of Longitudinally Extensive Transverse Myelitis
Mult Scler 18:271-285, Kitley, J.L.,et al, 2012
Herpes Encephalitis During Natalizumab Tretament in Multiple Sclerosis
Mult Scler J 18:909-911, Kwiatkowski, A.,et al, 2012
Epstein-Barr Virus Infections of the Nervous System
www.medlink.com, Nov, Amlie-Lefond,C., 2011
Inflammatory Cortical Demyelination in Early Sclerosis
NEJM 365:2188-2197, Lucchinetti, C.F.,et al, 2011
Evidence-based Guideline: Clinical Evaluation and Treatment of Transverse Myelitis
Neurol 77:2128-2134, Scott, T.F.,et al, 2011
Presence of Intracranial Artery Calcification Is Associated with Mortality and Vascular Events in Patients with Ischemic Stroke after Hospital Discharge
Stroke 42:3447-3453, Bugnicourt, J.M.,et al, 2011
Multiple Sclerosis-Quenching the Flames of Inflammation
Lancet 378:1759-1760, , 2011
Differential Features of Carotid and Vertebral Artery Dissections
Neurol 77:1174-1181, Debette, S.,et al, 2011
Does Therapeutic Hypothermia Affect Time to Awakening in Cardiac Arrest Survivors?
Neurol 77:1346-1350, Fugate, J.E.,et al, 2011
Syndrome of Inappropriate Antidiuresis May Herald or Accompany Neuromyelitis Optica
Neurol 77:1644-1645, Iorio, R.,et al, 2011
Hypereosinophilia in Patients with Multiple Sclerosis Treated with Natalizumab
Neurol 77:1561-1564, Abbas, M.,et al, 2011
Yellow Fever Vaccination and Increased Relapse Rate in Travelers with Multiple Sclerosis
Arch Neurol 68:1267-1271, Farez, M.F. and Correale, J., 2011
Longitudinal Change of Biomakers in Cognitive Decline
Arch Neurol 68:1257-1266,1237, Lo, R.Y.,et al, 2011
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
NEJM 365:1293-1303, OConnor, P.,et al, 2011
Drug-Resistant Epilepsy
NEJM 365:919-26, Kwan, P.,et al, 2011
N-methyl-D-aspartate Receptor Autoimmune Encephalitis Presenting With Opsoclonus-Myoclonus
Arch Neurol 68:1069-1072, Smith, J.H.,et al, 2011
Azathioprine
Neurol 77:659-666, Costanzi, C.,et al, 2011
Balos Concentric Sclerosis
NEJM 365:742, Wengert, O.,et al, 2011
Cost-effectiveness of disease-modifying therapy for multiple sclerosis
Neurol 77:355-363, Noyes, K.,et al, 2011
Disability, distress and unemployment in neurology outpatients with symptoms unexplained by organic disease
JNNP 82:810-813, 710, Carson, A.,et al, 2011
Neurological disturbances caused by intravascular lymphomatosis
Brain Nerve 63:443-449, Mizutani, T., 2011
Presentation, Diagnosis, Pathophysiology, and Treatment of the Neurological Features of Sturge-Weber Syndrome
The Neurologist 17:179-184, Comi, A.M., 2011
Primary Central Nervous System Lymphoma in a Patient Treated with Natalizumab
Ann Neurol 69:1060-1062, Phan-Ba, R.,et al, 2011
Clinical and MRI characteristics of acute migrainous infarction
Neurol 76:1911-1917, Wolf, M.E.,et al, 2011
Efficacy and Safety of Mitoxantrone in Patients with Highly Relapsing Neuromyelitis Optica
Arch Neurol 68:473-479, Kim, S.H.,et al, 2011
MRI Only Conversion to Multiple Sclerosis Following a Clinically Isolated Syndrome
JNNP 82:176-179, Chard,D.T.,et al, 2011
CSF Complements Serum for Evaluating Paraneoplastic Antibodies and NMO-IgG
Neurol 76:1108-1110, McKeon,A.,et al, 2011
Nonconvulsive Seizures are Common in Critically Ill Children
Neurol 76:1071-1074, Abend,N.S.,et al, 2011
Mechanisms of Fingolimods Efficacy and Adverse Effects in Multiple Sclerosis
Ann Neurol 69:759-777, Cohen, J.A. & Chun, J., 2011
Phase III Dose-Comparison Study of Glatiramer Acetate for Multiple Sclerosis
Ann Neurol 69:75-82, Comi,G.,et al, 2011
Prior Suggestive Symptoms in One-Third of Patients Consulting for a "First" Demyelinating Event
JNNP 82:323-325, Gout,O.,et al, 2011
When A Brain Lesion Necessitates Chest CT
Conn Med 75:143-146, Finelli,P.F., 2011
Evidence-Based Guideline Update: Plasmapheresis in Neurologic Disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 76:294-300, Cortese,I.,et al, 2011
Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria
Ann Neurol 69:292-302, 234, Polman,C.H.,et al, 2011
Recurrent Ischemic Events in Young Adults After First-Ever Ischemic Stroke
Ann Neurol 68:661-671, Putaala,J.,et al, 2010
Evidence for Acute Neurotoxicity After Chemotherapy
Ann Neurol 68:806-815, Petzold,A.,et al, 2010
Dysexecutive Syndrome: Diagnostic Criteria and Validation Study
Ann Neurol 68:855-864, Godefroy,O.,et al, 2010
Pregnancy and Fetal Outcomes After Interferon-b Exposure in Multiple Sclerosis
Neurol 75:1794-1802, Amato,M.P.,et al, 2010
Tourettes Syndrome
NEJM 363:2332-2338, Kurlan,R., 2010
Cerebral Amyloid Angiopathy
UpToDate: May 2010, Greenberg,S.M.,et al, 2010
Cardiotoxicity and Other Adverse Events Associated With Mitoxantrone Treatment for MS
Neurol 74:1822-1826, Kingwell,E., et al, 2010
Neuromyelitis Optica Treatment: Analysis of 36 Patients
Arch Neurol 67:1131-1136, Bichuetti,D.B.,et al, 2010
Safety and Efficacy of Natalizumab in Children With Multiple Sclerosis
Neurol 75:912-917, Ghezzi,A.,et al, 2010